CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (343)	3/13/1998 9:18:00 AM
From: Rudy Saucillo	Read Replies (1) of 675

<<Not the kind of cash conservation one would expect from a company seeking to maximize its ability to develop its R&D programs.>> Agreed. One possibility for reducing burn via layoffs and reducing cash (dividend payment and severance expenses) may be to make themselves more attractive for acquisition. Particularly by a pharma not needing the cash and not wanting the extra dilution necessary for it. I don't see the dividend as especially attractive for investors in the near term. Given the technology value of zero, it's more or less a buck in cash in exchange for a buck reduction in stock price. Rudy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next